个体化短疗程抗生素治疗与常规长疗程治疗呼吸机相关性肺炎(REGARD-VAP):多中心、个体随机、开放标签、非劣效性试验
这项在尼泊尔、新加坡和泰国6家医院39个ICU进行的个体随机、开放标签、分层非劣效-优效性试验,纳入461例符合美国CDC国家医疗安全网络VAP标准、机械通气≥48小时且使用培养指导抗生素的成人。患者退热48小时且血流动力学稳定后按1:1随机分为个体化短疗程(≤7天,可短至3-5天)或常规长疗程(≥8天,具体时长由主管医生决定)。主要终点为60天死亡或肺炎复发复合终点,非劣效界值预设为12%。短疗程组中位抗生素疗程6天(IQR 5-7),常规组14天(IQR 10-21)。短疗程组231例中95例(41%)达到主要终点,常规组229例中100例(44%)达到主要终点,风险差-3%(单侧95%CI -∞至5%),在意向治疗和符合方案人群中均满足非劣效性,但未确立优效性。符合方案人群中,常规组抗生素副作用发生率为86/224(38%),短疗程组为17/211(8%),风险差-31%(95%CI -37至-25%;p<0.0001)。作者认为,以临床反应为指导的个体化短疗程可减少抗生素使用和副作用。
要点
- 纳入标准:成人(≥18岁)符合美国CDC国家医疗安全网络VAP标准、机械通气≥48小时、使用培养指导抗生素;培养阴性者按当地抗菌谱或指南经验性选药。
- 随机时机:退热持续48小时且血流动力学稳定后,1:1随机分为个体化短疗程(≤7天,可短至3-5天)或常规长疗程(≥8天,时长由主管医生决定)。
- 主要终点60天死亡或肺炎复发复合终点:短疗程组95/231(41%)vs 常规组100/229(44%),风险差-3%(单侧95%CI -∞至5%),满足预设12%非劣效界值,未确立优效性。
- 符合方案人群中抗生素副作用:常规组86/224(38%)vs 短疗程组17/211(8%),风险差-31%(95%CI -37至-25%;p<0.0001)。
- 中位抗生素疗程:短疗程组6天(IQR 5-7)vs 常规组14天(IQR 10-21)。
适用人群与场景
- 纳入:成人(年龄≥18岁)符合美国CDC国家医疗安全网络VAP标准,机械通气≥48小时,并使用培养指导抗生素;培养阴性者依据当地微生物实验室抗菌谱或现行当地指南经验性选药。
- 场景:6家医院39个ICU(尼泊尔、新加坡、泰国)。
- 随机条件:退热持续48小时且血流动力学稳定后。
诊断标准与关键阈值
- VAP诊断标准:美国CDC国家医疗安全网络(National Healthcare Safety Network)标准。
- 非劣效界值:预设为12%,需在意向治疗和符合方案人群分析中同时满足。
处置流程与药物剂量
- 个体化短疗程组:抗生素疗程≤7天,可短至3-5天,具体由临床反应个体化决定。
- 常规长疗程组:抗生素疗程≥8天,具体时长由主管临床医生决定。
- 随机分组:采用可变区组大小(8、10、12)的置换区组,按研究中心分层,1:1分配。
- 盲法:独立评估者(评估肺炎复发)和参与者对分组设盲,临床医生不设盲。
研究设计与关键结果
- 研究设计:4期、个体随机、开放标签、分层非劣效-优效性试验,在尼泊尔、新加坡和泰国的6家医院39个ICU进行。
- 样本量:2018年5月25日至2022年12月16日共纳入461例,随机分为短疗程组(n=232)和常规组(n=229);中位年龄64岁(IQR 51-74),女性181例(39%)。
- 分析人群:排除1例退出后,意向治疗分析460例(短疗程组231例、常规组229例);符合方案人群435例(接受分配治疗且符合纳入标准)。
- 中位抗生素疗程:短疗程组6天(IQR 5-7)vs 常规组14天(IQR 10-21)。
- 主要终点(60天死亡或肺炎复发):短疗程组95/231(41%)vs 常规组100/229(44%),风险差-3%(单侧95%CI -∞至5%);符合方案人群结果相似。
- 非劣效性:在意向治疗和符合方案人群分析中均满足非劣效性;与常规治疗相比未确立优效性。
- 抗生素副作用(符合方案人群):常规组86/224(38%)vs 短疗程组17/211(8%),风险差-31%(95%CI -37至-25%;p<0.0001)。
证据类型、等级与局限
- 证据类型:4期、多中心、个体随机、开放标签、非劣效性试验(NCT03382548)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,以临床反应为指导的个体化短疗程抗生素(≤7天,可短至3-5天)对于成人VAP,在60天死亡和肺炎复发方面非劣于长疗程,且与抗生素使用量和副作用显著减少相关。
- 作者认为,个体化短疗程抗生素治疗VAP可能有助于减少副作用负担和抗生素耐药风险,适用于高资源和资源有限环境。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ventilator-associated pneumonia (VAP) is associated with increased mortality, prolonged hospitalisation, excessive antibiotic use and, consequently, increased antimicrobial resistance. In this phase 4, randomised trial, we aimed to establish whether a pragmatic, individualised, short-course antibiotic treatment strategy for VAP was non-inferior to usual care.
METHODS: We did an individually randomised, open-label, hierarchical non-inferiority-superiority trial in 39 intensive care units in six hospitals in Nepal, Singapore, and Thailand. We enrolled adults (age ≥18 years) who met the US Centers for Disease Control and Prevention National Healthcare Safety Network criteria for VAP, had been mechanically ventilated for 48 h or longer, and were administered culture-directed antibiotics. In culture-negative cases, empirical antibiotic choices were made depending on local hospital antibiograms reported by the respective microbiology laboratories or prevailing local guidelines. Participants were assessed until fever resolution for 48 h and haemodynamic stability, then randomly assigned (1:1) to individualised short-course treatment (≤7 days and as short as 3-5 days) or usual care (≥8 days, with precise durations determined by the primary clinicians) via permuted blocks of variable sizes (8, 10, and 12), stratified by study site. Independent assessors for recurrent pneumonia and participants were masked to treatment allocation, but clinicians were not. The primary outcome was a 60-day composite endpoint of death or pneumonia recurrence. The non-inferiority margin was prespecified at 12% and had to be met by analyses based on both intention-to-treat (all study participants who were randomised) and per-protocol populations (all randomised study participants who fulfilled the eligibility criteria, met fitness criteria for antibiotic discontinuation, and who received antibiotics for the duration specified by their allocation group). This study is registered with ClinicalTrials.gov, number NCT03382548.
FINDINGS: Between May 25, 2018, and Dec 16, 2022, 461 patients were enrolled and randomly assigned to the short-course treatment group (n=232) or the usual care group (n=229). Median age was 64 years (IQR 51-74) and 181 (39%) participants were female. 460 were included in the intention-to-treat analysis after excluding one withdrawal (231 in the short-course group and 229 in the usual care group); 435 participants received the allocated treatment and fulfilled eligibility criteria, and were included in the per-protocol population. Median antibiotic treatment duration for the index episodes of VAP was 6 days (IQR 5-7) in the short-course group and 14 days (10-21) in the usual care group. 95 (41%) of 231 participants in the short-course group met the primary outcome, compared with 100 (44%) of 229 in the usual care group (risk difference -3% [one-sided 95% CI -∞ to 5%]). Results were similar in the per-protocol population. Non-inferiority of short-course antibiotic treatment was met in the analyses, although superiority compared with usual care was not established. In the per-protocol population, antibiotic side-effects occurred in 86 (38%) of 224 in the usual care group and 17 (8%) of 211 in the short-course group (risk difference -31% [95% CI -37 to -25%; p<0·0001]).
INTERPRETATION: In this study of adults with VAP, individualised shortened antibiotic duration guided by clinical response was non-inferior to longer treatment durations in terms of 60-day mortality and pneumonia recurrence, and associated with substantially reduced antibiotic use and side-effects. Individualised, short-course antibiotic treatment for VAP could help to reduce the burden of side-effects and the risk of antibiotic resistance in high-resource and resource-limited settings.
FUNDING: UK Medical Research Council; Singapore National Medical Research Council.
TRANSLATIONS: For the Thai and Nepali translations of the abstract see Supplementary Materials section.
参考来源
- Mo Y, Booraphun S, Li AY, et al. Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial. Lancet Respir Med. 2024. PMID: 38272050. doi:10.1016/S2213-2600(23)00418-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。